A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

ABSTRACTRelapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median ag...

Full description

Bibliographic Details
Main Authors: Robin Noel, Christophe Zemmour, Catalina Montes de Oca, Nawel Belmecheri, Thérèse Aurran-Schleinitz, Diane Coso, Leonor Lopez Almeida, Lénaïg Mescam, Norbert Vey, Jean Sébastien Bladé, Borhane Slama, Reda Bouabdallah, Jean-Marc Schiano de Colella
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
Relapsed/refractory diffuse large B cell lymphoma
rituximab and lenalidomide
clinical trial
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2207948

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2023.2207948

Similar Items